相似文献
1
Letter About: Risk Factors for Mortality in Patients with COVID-19 in New York City.
J Gen Intern Med. 2021 Mar;36(3):811-812. doi: 10.1007/s11606-020-06369-x. Epub 2021 Jan 11.
2
Estimating the infection-fatality risk of SARS-CoV-2 in New York City during the spring 2020 pandemic wave: a model-based analysis.
Lancet Infect Dis. 2021 Feb;21(2):203-212. doi: 10.1016/S1473-3099(20)30769-6. Epub 2020 Oct 19.
3
Letter regarding "Outcomes of a COVID-19 recovery program for patients hospitalized with SARS-CoV-2 infection in New York City: A prospective cohort study".
PM R. 2021 Aug;13(8):925-926. doi: 10.1002/pmrj.12653. Epub 2021 Jul 20.
4
Reply to Letter regarding "Outcomes of a COVID-19 recovery program for patients hospitalized with SARS-CoV-2 infection in New York City: A prospective cohort study".
PM R. 2021 Aug;13(8):927-928. doi: 10.1002/pmrj.12629. Epub 2021 Jul 20.
5
In Reply to the Letter to the Editor Regarding '"Staying Home"-Early Changes in Patterns of Neurotrauma in New York City during the COVID-19 Pandemic'.
World Neurosurg. 2021 Feb;146:410. doi: 10.1016/j.wneu.2020.11.010.
6
Letter to the Editor Regarding "'Staying Home'-Early Changes in Patterns of Neurotrauma in New York City During the COVID-19 Pandemic".
World Neurosurg. 2021 Feb;146:407-409. doi: 10.1016/j.wneu.2020.10.165.
7
Obesity and COVID-19 in New York City: A Retrospective Cohort Study.
Ann Intern Med. 2020 Nov 17;173(10):855-858. doi: 10.7326/M20-2730. Epub 2020 Jul 6.
8
ABO blood type association with SARS-CoV-2 infection mortality: A single-center population in New York City.
Transfusion. 2021 Apr;61(4):1064-1070. doi: 10.1111/trf.16339. Epub 2021 Mar 5.
9
Excess neurological death in New York City after the emergence of COVID-19.
J Neurol. 2021 Jun;268(6):2026-2028. doi: 10.1007/s00415-020-10084-2. Epub 2020 Jul 20.
10
Coronavirus Disease 2019 (COVID-19) Outbreaks at 2 Construction Sites-New York City, October-November 2020.
Clin Infect Dis. 2021 Jul 15;73(Suppl 1):S81-S83. doi: 10.1093/cid/ciab312.
本文引用的文献
1
Cardiac Toxicity of Chloroquine or Hydroxychloroquine in Patients With COVID-19: A Systematic Review and Meta-regression Analysis.
Mayo Clin Proc Innov Qual Outcomes. 2021 Feb;5(1):137-150. doi: 10.1016/j.mayocpiqo.2020.10.005. Epub 2020 Nov 2.
2
Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19.
Int J Infect Dis. 2020 Aug;97:396-403. doi: 10.1016/j.ijid.2020.06.099. Epub 2020 Jul 2.
3
Risk Factors for Mortality in Patients with COVID-19 in New York City.
J Gen Intern Med. 2021 Jan;36(1):17-26. doi: 10.1007/s11606-020-05983-z. Epub 2020 Jun 30.
4
Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area.
JAMA. 2020 May 26;323(20):2052-2059. doi: 10.1001/jama.2020.6775.
5
Survival biases lead to flawed conclusions in observational treatment studies of influenza patients.
J Clin Epidemiol. 2017 Apr;84:121-129. doi: 10.1016/j.jclinepi.2017.01.008. Epub 2017 Feb 7.
6
Conclusion about the association between valve surgery and mortality in an infective endocarditis cohort changed after adjusting for survivor bias.
J Clin Epidemiol. 2010 Feb;63(2):130-5. doi: 10.1016/j.jclinepi.2008.06.022.
Zotero 插件